PrEPMedication.com Truvada · Descovy · Apretude · Lenacapavir · 2-1-1
Every option, side by side

Compare PrEP Medications: Truvada vs Descovy vs Apretude vs Lenacapavir

All of these prevent HIV — they differ in how you take them, who they’re approved for, how they affect your kidneys, bones and weight, and cost. Use the table to find your fit, then read the deep-dive for any medicine.

Medically reviewed by the Prepmedication.com Medical Review Team Last reviewed 3 July 2026 · Next review Jan 2027 · Written to CDC, WHO & USPSTF guidance · How we review →

Full comparison table

 Truvada (TDF)Descovy (TAF)Apretude (CAB)Lenacapavir2-1-1
FormDaily pillDaily pillInjection / 2 moInjection / 6 moPills around sex
Approved forAll exposuresAnal onlyAll exposuresAll exposuresAnal, MSM
Time to protect (anal)~7 days~7 daysOn scheduleAfter initiationPre-dose 2–24 h
Time to protect (vaginal)~20 daysNot approvedOn scheduleAfter initiationNot for vaginal
KidneyMonitorMinimalNoneNoneMonitor
Bone~2–4% yr1NegligibleNoneNoneLow
Weight/lipidsNeutral+1–3 kgMinimalMinimalNeutral
Signature effectEarly nauseaWeight/lipidsInjection-siteInjection-siteFewer pills
PregnancyRecommendedLimited dataCan useEmerging dataNo
CostCheapestBrandHighHighLow (generic)

“On schedule” = protective once the injection series is given at the recommended times. Read each medicine’s full guide below.

Which PrEP is right for you?

⚡ On-demand “2-1-1” dosing — read this first

For anal sex, Truvada can be taken around sex rather than daily: 2 pills 2–24 h before, then 1 pill at 24 h and 1 pill at 48 h. It’s convenient for infrequent, plannable sex — but it comes with firm limits.

⚠️ Important safety & legal note. On-demand 2-1-1 dosing is WHO-recommended for MSM in Europe, Canada and Australia, but it is NOT FDA-approved in the US and has not been studied for vaginal exposure. It must not be used for vaginal sex or with Descovy/injectables. Consult your provider before using this regimen.

🆕 Lenacapavir (Yeztugo) — the twice-a-year option

Approved by the FDA in 2025, lenacapavir is a long-acting capsid inhibitor given as a subcutaneous injection just twice a year. In the PURPOSE trials it showed near-complete protection, including in cisgender women. It’s the newest and least-frequent option — availability and cost are still settling. See it in context on the PrEP Options page →

Still comparing?

Read a full side-effect deep-dive for any medicine, or check whether your other medications interact with PrEP.

Full side-effect guides

★ Feature · alternatives

PrEP alternatives: other ways to prevent HIV

PrEP is highly effective, but it's part of a bigger toolkit. Depending on your situation, alternatives or add-ons include:

🔬 Sources & review

✔ Last medically reviewed: 3 July 2026 · Prepmedication.com Medical Review Team · Next review due: January 2027 · How we review →

Medical disclaimer. This comparison is general information, not a diagnosis or prescription. Approvals and dosing vary by country and change over time; always confirm your plan with a qualified clinician. If you may have been exposed to HIV in the last 72 hours, see PEP now.

© 2026 PrEPMedication.com
Symptom Map · PrEP Options · Compare · Drug Checker · PEP
Truvada · Descovy · Apretude · Editorial policy · Privacy